The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Incretin-based therapies for type 2 diabetes mellitus
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Three pivotal, phase III clinical trials, each of 30 weeks duration, examined the efficacy of twice-daily injections of 5 µg or 10 µg exenatide in individuals who had T2DM that was inadequately controlled with a sulfonylurea and/or metformin”
BackgroundNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Self-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Rosenstock, J., Brazg, R., Andryuk, P. J., Lu, K., & Stein, P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.007 · Cited by 514
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes
Lankas, G. R., Leiting, B., Roy, R. S., Eiermann, G. J., Beconi, M. G., Biftu, T., Chan, C.-C., Edmondson, S., Feeney, W. P., He, H., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2988 · Cited by 491
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Kim, D., MacConell, L., Zhuang, D., Kothare, P. A., Trautmann, M., Fineman, M., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 446
Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R., & Trautmann, M. (2007) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 437
Zinman, B., Hoogwerf, B. J., Durán García, S., Milton, D. R., Giaconia, J. M., Kim, D. D., Trautmann, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 427
Kennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 427
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386
Self-citationAddition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
Fonseca, V., Schweizer, A., Albrecht, D., Baron, M. A., Chang, I., & Dejager, S. (2007) · Diabetologia · doi:10.1007/s00125-007-0633-0 · Cited by 369
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes
Pi-Sunyer, F. X., Schweizer, A., Mills, D., & Dejager, S. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.12.009 · Cited by 312
Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309
Self-citationTherapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes
Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., & Schweizer, A. (2007) · Diabetes Care · doi:10.2337/dc06-1815 · Cited by 270
Raz, I., Chen, Y., Wu, M., Hussain, S., Kaufman, K. D., Amatruda, J. M., Langdon, R. B., Stein, P. P., & Alba, M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260925 · Cited by 260
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
Chan, J. C. N., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & Williams‐Herman, D. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00914.x · Cited by 238
DeFronzo, R. A., Fleck, P. R., Wilson, C. A., Mekki, Q., & on behalf of the Alogliptin Study 010 Group (2008) · Diabetes Care · doi:10.2337/dc08-1035 · Cited by 227
Scott, R., Loeys, T., Davies, M. J., Engel, S. S., & for the Sitagliptin Study 801 Group (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00839.x · Cited by 223
Nauck, M. A., Ellis, G. C., Fleck, P. R., Wilson, C. A., Mekki, Q., & for the Alogliptin Study 008 Group (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01933.x · Cited by 205
Matthews, J. E., Stewart, M. W., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M. A., & for the Albiglutide Study Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1518 · Cited by 198
Bolli, G., Dotta, F., Rochotte, E., & Cohen, S. E. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00820.x · Cited by 192
New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 187
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Cervera, A., Wajcberg, E., Sriwijitkamol, A., Fernandez, M., Zuo, P., Triplitt, C. L., Musi, N., DeFronzo, R. A., & Cersósimo, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2008 · Cited by 165
Baggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137
Self-citationRaufman, J., Singh, L., Singh, G., & Eng, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36628-1 · Cited by 136
Effect of Exenatide on ?? Cell Function After Islet Transplantation in Type 1 Diabetes
Ghofaili, K. A., Fung, M., Ao, Z., Meloche, M. R., Shapiro, R. J., Warnock, G. L., Elahi, D., Meneilly, G. S., & Thompson, D. M. (2007) · Transplantation · doi:10.1097/01.tp.0000251379.46596.2d · Cited by 129
Exenatide and rare adverse events.
Ahmad, S. R., & Swann, J. (2008) · PubMed · Cited by 122
Seino, Y., Rasmussen, M. F., Zdravkovic, M., & Kaku, K. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.03.018 · Cited by 117
Froud, T., Faradji, R. N., Pileggi, A., Messinger, S., Baidal, D. A., Ponte, G., Cure, P., Monroy, K., Mendez, A. J., Selvaggi, G., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31817c4ab3 · Cited by 83
Schmitz, O., Russell-Jones, D. L., Vaag, A. A., Sethi, B. K., Lalic, N. M., Antić, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2008) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(08)24116-x · Cited by 45
Garcia‐Soria, G., González-Gálvez, G., Argoud, G., Gerstman, M., Littlejohn, T. W., Schwartz, S. L., O'Farrell, A. M., Li, X., Cherrington, J. M., Bennett, C., et al. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00868.x · Cited by 29
Cited by
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Paul, S., & Candelario-Jalil, E. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113518 · Cited by 748
Metadata
- Authors
- Lovshin, J. A., & Drucker, D. J.
- Venue
- Nature Reviews Endocrinology
- Published
- 2009-05
- Volume
- 5
- Issue
- 5
- Pages
- 262-269
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W1967256054
- Cited by
- 649
- References
- 52
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.